MHRA Draws the Line on AI Scribes: What the New Guidance Means for NHS Suppliers
Published yesterday, the MHRA's long-awaited ambient voice technology guidance finally tells developers which AI scribe functions need medical device approval and which don't. For a market that has been operating in deliberate ambiguity for over a year, the stakes couldn't be higher.
The Regulatory Fog Lifts - Mostly
Yesterday morning, the Medicines and Healthcare products Regulatory Agency published guidance clarifying how existing medical device law applies to ambient voice technology (AVT) products used in health and care settings in Great Britain. The document, developed in close partnership with NHS England, had been widely anticipated across the healthtech sector. By some accounts, the absence of clarity had been slowing procurement decisions across dozens of NHS trusts.
AVT products, commonly marketed as AI scribes, record and summarise clinical conversations, reducing time spent on documentation and freeing clinicians to concentrate on patients. Their adoption has been rapid. NHS England is already rolling out AI notetaking tools nationally as part of a £10 billion technology investment programme announced earlier this month, with an ambition to make the NHS the most AI-enabled health system in the world.
Advertisement
Rapid adoption without regulatory clarity is exactly the kind of scenario that keeps MHRA and patient safety advocates up at night.
Where the Boundary Now Sits
The new guidance confirms that AVT products intended solely for transcription, summarising clinical conversations, drafting letters, or suggesting clinical codes for a clinician to review do not qualify as regulated medical devices under UK MDR. That is a commercially significant finding: it removes compliance overhead for a wide class of tools and should accelerate procurement.
Where a product supports diagnosis or treatment, however, regulatory protections still apply. The MHRA has provided worked examples of AVT products that do and do not qualify as medical devices, alongside detailed reasoning for each conclusion. Law firm Bristows, commenting on the guidance, noted that if a manufacturer fails to sufficiently limit an AVT product's functionality to align with its stated intended purpose, the MHRA may treat that as an implied claim of medical intent, bringing the product squarely within its regulatory jurisdiction.
That is a point worth sitting with. In a competitive market where vendors routinely over-engineer features to differentiate, the temptation to let functionality creep beyond the intended purpose is real. The guidance penalises that creep with a step-change in compliance burden.
Context: 18 Months of Regulatory Drift
The urgency of this clarification is best understood against its backstory. In February 2025, MHRA guidance on Digital Mental Health Technologies introduced ambiguity about how UK MDR applied to AVT products. NHS England then published its own dedicated AVT guidance which, according to Bristows' analysis, took the contentious position that all AVT products qualified as medical devices. The two bodies were publicly out of step.
Yesterday's release resolves that directly. NHS England has revised its own guidance to remove its explanation of how UK MDR applies to AVT products, ceding that interpretive territory to the MHRA. The MHRA has simultaneously updated the DMHT Guidance to align with the new AVT framework.
Rob Thompson, chief digital, data and technology officer at NHS England, said the two organisations would now begin rolling out AVT tools "safely, consistently and at scale." That word, consistently, is doing a lot of work. The previous inconsistency had real costs.
Suppliers and the Brand Gap
For companies building in this space, the regulatory runway is now clearer. Brand infrastructure, though, hasn't kept pace. AI Business Dispatch analysis of Companies House and IPO data (as of July 2026) shows only 73 new SIC 86.10 companies were incorporated in Q3 2026, a 76.6% fall versus the prior period, while Class 44 UK trademark filings dropped to 675 in the same quarter, down 70.6%. Most strikingly, 98.3% of active SIC 86.10 companies hold no Class 44 trademark at all.
Class 44 covers medical and health services, precisely the commercial territory AVT suppliers are operating in. The brand protection gap matters. In a market about to see accelerated NHS procurement, vendors without registered marks in Class 44 risk losing the ability to defend their product names against well-capitalised competitors or NHS framework incumbents who move faster on IP.
The guidance does not apply to Northern Ireland, which remains subject to the EU Medical Devices Regulation 2017/745. For suppliers operating across both markets, that dual compliance obligation persists.
What Comes Next
Yesterday's guidance is explicitly not a change in law. It is an interpretation of existing regulation applied to a fast-moving technology category. The longer-term framework, including Predetermined Change Control Plans for adaptive AI systems formalised in the draft Medical Devices (Amendment) Regulations 2026 released in May, remains in progress.
The MHRA's AI Airlock regulatory sandbox, now in its third phase with £1.2 million per year from the Department of Health and Social Care through to 2029, continues to generate the evidence base that will eventually underpin that framework. Yesterday's guidance feeds directly into the work of the National Commission into the Regulation of AI in Healthcare.
The fog has lifted over one important patch of ground. The rest of the regulatory map for AI in medicine is still being drawn.